Privileged structures: Applications in drug discovery

被引:532
作者
DeSimone, RW [1 ]
Currie, KS [1 ]
Mitchell, SA [1 ]
Darrow, JW [1 ]
Pippin, DA [1 ]
机构
[1] Gellular Genomics Inc, Branford, CT 06405 USA
关键词
privileged structures; drug like properties; combinatorial libraries; focused libraries;
D O I
10.2174/1386207043328544
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Over the past 15 years the privileged structure concept has emerged as a fruitful approach to the discovery of novel biologically active molecules. Privileged structures are molecular scaffolds with versatile binding properties, such that a single scaffold is able to provide potent and selective ligands for a range of different biological targets through modification of functional groups. In addition, privileged structures typically exhibit good drug-like properties, which in turn leads to more drug-like compound libraries and leads. The net result is the production of high quality leads that provide a solid foundation for further development. The identification of privileged structures will be discussed, emphasizing the importance of understanding the structure-target relationships that confer "privileged" status. This understanding allows privileged structure based libraries to be targeted at distinct target families (e.g. GPCRs, LGIC, enzymes/kinases). Privileged structures have been successfully exploited across and within different target families and promises to be an effective approach to the discovery and optimization of novel bioactive molecules. The application of the privileged structure approach, both in traditional medicinal chemistry and in the design of focused libraries, will be discussed with the aid of illustrative examples.
引用
收藏
页码:473 / 493
页数:21
相关论文
共 134 条
[11]   The design of combinatorial libraries using properties and 3D pharmacophore fingerprints [J].
Beno, BR ;
Mason, JS .
DRUG DISCOVERY TODAY, 2001, 6 (05) :251-258
[12]   Absorption classification of oral drugs based on molecular surface properties [J].
Bergström, CAS ;
Strafford, M ;
Lazorova, L ;
Avdeef, A ;
Luthman, K ;
Artursson, P .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (04) :558-570
[13]   A combinatorial approach toward the discovery of non-peptide, subtype-selective somatostatin receptor ligands [J].
Berk, SC ;
Rohrer, SP ;
Degrado, SJ ;
Birzin, ET ;
Mosley, RT ;
Hutchins, SM ;
Pasternak, A ;
Schaeffer, JM ;
Underwood, DJ ;
Chapman, KT .
JOURNAL OF COMBINATORIAL CHEMISTRY, 1999, 1 (05) :388-396
[14]   Parallel solution- and solid-phase synthesis of spiropyrrolo-pyrroles as novel neurokinin receptor ligands [J].
Bleicher, KH ;
Wüthrich, Y ;
Adam, G ;
Hoffmann, T ;
Sleight, AJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (21) :3073-3076
[15]   Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening [J].
Boehm, HJ ;
Boehringer, M ;
Bur, D ;
Gmuender, H ;
Huber, W ;
Klaus, W ;
Kostrewa, D ;
Kuehne, H ;
Luebbers, T ;
Meunier-Keller, N .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (14) :2664-2674
[16]   Recognition of privileged structures by G-protein coupled receptors [J].
Bondensgaard, K ;
Ankersen, M ;
Thogersen, H ;
Hansen, BS ;
Wulff, BS ;
Bywater, RP .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (04) :888-899
[17]   Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxo-hexahydro-pyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease.: 1.: The α-methyl-trans-lactam template [J].
Borthwick, AD ;
Angier, SJ ;
Crame, AJ ;
Exall, AM ;
Haley, TM ;
Hart, GJ ;
Mason, AM ;
Pennell, AMK ;
Weingarten, GG .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (23) :4452-4464
[18]  
Boyce HW, 1997, AM J GASTROENTEROL, V92, pS34
[19]  
CHABALA JC, 1996, INT S 4 ED SEPT 12 1
[20]   Prediction of pharmacokinetic properties using experimental approaches during early drug discovery [J].
Chaturvedi, PR ;
Decker, CJ ;
Odinecs, A .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2001, 5 (04) :452-463